Core Insights - Zevra Therapeutics, Inc. announced presentations on MIPLYFFA (arimoclomol) at the NNPDF Conference, highlighting its role as the first FDA-approved treatment for Niemann-Pick disease type C (NPC) [1][2] - MIPLYFFA is indicated for use in combination with miglustat for treating neurological manifestations of NPC in patients aged 2 years and older [7][6] Presentation and Research Findings - Dr. Barbara K. Burton presented an overview of MIPLYFFA, emphasizing its unique mechanism that improves lysosomal function and halts disease progression at 12 months in a pivotal study [2][3] - The pivotal trial demonstrated that arimoclomol combined with miglustat halted disease progression compared to placebo, confirmed by a 48-month open-label extension study [4][6] - Two posters were presented: one detailing long-term effectiveness and safety of arimoclomol, and another providing mechanistic evidence of arimoclomol's action through the CLEAR network [4][5] Drug Mechanism and Clinical Significance - MIPLYFFA enhances the activation of transcription factors TFEB and TFE3, leading to the upregulation of CLEAR genes and improved lysosomal function [6][17] - The drug has shown to reduce unesterified cholesterol in NPC fibroblasts, although the clinical significance of this finding remains to be fully understood [6] Company Overview - Zevra Therapeutics focuses on developing therapies for rare diseases with limited treatment options, aiming to create transformational therapies through data-driven strategies [18]

公众号记得加星标⭐️，第一时间看推送不会错过。 成立于1990年的Rambus公司，是接口IP和安全IP领域的先驱者。 凭借其创新的高速接口技术， Rambus重新定义了内存与系统间的数据传输标准，其DDR内存接口、HBM3/4和PCIe 5/6 等解决方 案 显 著 提 升 了 数 据 中 心 、 边 缘 计 算 等 场 景 的 性 能 上 限 。 同 时 ， 面 对 日 益 复 杂 的 网 络 安 全 威 胁 ， Rambus拥有许多安全IP解决方案，比如信任根技术、安全协议引擎、内联(inline)密码引擎、后量子 密码算法加速器核等。这些丰富的安全和接口IP解决方案帮助Rambus构建了强大的产品组合。 7月9日，针对AI和汽车两大热门方向，Rambus于北京丽亭华苑酒店举办技术探讨会。 届时，除了 Rambus 之 外 ， 其 他 行 业 合 作 伙 伴 包 括 M31 、 晶 心 科 技 、 Brightsight 、 ETAS 、 DPLSLab 、 CoMIRA、Riscure的多位技术专家将带来全天候的精彩分享。 日期 ： 2025年7月9日 ⏰ 时间 ： 8:30 - 17:30 地点 ： ...

Corporate Presentation June 2025 Forward-Looking Statements and Topline Data Disclaimer The material in this presentation (this "Presentation") regarding Kezar Life Sciences, Inc. ("Kezar") is for informational purposes only. This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expect," "believe", "plan" and similar expressions (as well as other words or expressions referencing future events, ...

Core Viewpoint - Rambus, established in 1990, is a pioneer in interface IP and security IP, enhancing data transmission standards and addressing complex network security threats through innovative solutions [1] Group 1: Company Overview - Rambus has redefined data transmission standards between memory and systems with its high-speed interface technologies, including DDR memory interfaces, HBM3/4, and PCIe 5/6, significantly improving performance in data centers and edge computing [1] - The company offers a robust product portfolio with various security IP solutions, such as root of trust technology, secure protocol engines, inline cryptographic engines, and post-quantum cryptography accelerators [1] Group 2: Event Details - Rambus is hosting a technology seminar on July 9, 2025, at the Beijing Liting Huayuan Hotel, focusing on AI and automotive sectors [2][3] - The event will feature industry partners and technical experts from companies like M31, Chipone, Brightsight, ETAS, DPLSLab, CoMIRA, and Riscure, providing insights throughout the day [1] Group 3: Agenda Highlights - The morning session will cover silicon IP for AI and next-generation applications, discussing topics such as memory selection for training and inference, and the importance of PCIe and CXL in the AI era [5][6] - Afternoon discussions will focus on automotive security solutions, addressing trends and challenges faced by hardware and software designers in smart connected vehicles [6][7]

Company Overview - Zevra Therapeutics (ZVRA) shares increased by 5.1% to close at $9.41, with trading volume significantly higher than usual [1] - The stock has shown a 0.9% gain over the past four weeks [1] Product Performance - The rise in stock price is linked to positive investor sentiment regarding the initial uptake of Miplyffa (arimoclomol), which received FDA approval for Niemann-Pick disease type C in September 2024 [2] - Miplyffa generated sales of $17.1 million in Q1 2025 [2] Earnings Expectations - Zevra Therapeutics is projected to report quarterly earnings of $0.65 per share, reflecting a year-over-year increase of 235.4% [3] - Expected revenues for the upcoming quarter are $71.83 million, representing a 1514.2% increase from the same quarter last year [3] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a potential lack of momentum in earnings estimate revisions [4] Industry Context - Zevra Therapeutics is categorized under the Zacks Medical - Drugs industry, which includes other companies like Xeris Biopharma (XERS) [5] - Xeris Biopharma's stock closed 1.5% higher at $4.73, with a slight return of 0.2% over the past month [5] - Xeris Biopharma's consensus EPS estimate has also remained unchanged, with a year-over-year change of 70% [6]

在当今高速发展的半导体行业中，数据传输速度和安全性已成为关键挑战。随着人工智能、 联网车辆、5G和物联网的爆发式增长，市场对高性能计算和低功耗芯片的需求激增，而内存 带宽与数据处理安全性的瓶颈日益凸显。在这一背景下，接口IP和安全IP技术成为行业突破 的核心驱动力，它们直接决定了芯片的效能、兼容性及抗攻击能力。 成立于1990年的Rambus公司，正是这一领域的先驱者。凭借其创新的高速接口技术，Rambus重新 定义了内存与系统间的数据传输标准，其DDR内存接口、HBM3/4和PCIe 5/6 等解决方案显著提升 了数据中心、边缘计算等场景的性能上限。同时，面对日益复杂的网络安全威胁，Rambus拥有许 多安全IP解决方案，比如信任根技术、安全协议引擎、内联(inline)密码引擎、后量子密码算法加速 器核等。这些丰富的安全和接口IP解决方案帮助Rambus构建了强大的产品组合。 7月9日，针对AI和汽车两大热门方向，Rambus于北京丽亭华苑酒店举办技术探讨会。届时，除了 Rambus 之 外 ， 其 他 行 业 合 作 伙 伴 包 括 M31 、 晶 心 科 技 、 Brightsight 、 ETAS ...

Core Viewpoint - The semiconductor industry faces critical challenges in data transmission speed and security, driven by the explosive growth of AI, connected vehicles, 5G, and IoT, leading to increased demand for high-performance computing and low-power chips [1] Group 1: Industry Challenges and Innovations - The bottlenecks in memory bandwidth and data processing security are becoming increasingly prominent [1] - Interface IP and security IP technologies are identified as core drivers for breakthroughs in the industry, directly impacting chip performance, compatibility, and attack resistance [1] - Rambus, established in 1990, is a pioneer in this field, redefining data transmission standards between memory and systems with innovative high-speed interface technologies [1] Group 2: Rambus Solutions - Rambus offers solutions such as DDR memory interfaces, HBM3/4, and PCIe 5/6, significantly enhancing performance limits in data centers and edge computing [1] - The company provides a range of security IP solutions, including root of trust technology, security protocol engines, inline cryptographic engines, and post-quantum cryptography accelerators [1] - These comprehensive security and interface IP solutions contribute to a robust product portfolio for Rambus [1] Group 3: Upcoming Event - Rambus will host a technology discussion on July 9, 2025, in Beijing, focusing on AI and automotive sectors, featuring industry partners and technical experts [2][3] - The morning session will cover the latest interface and security IP solutions for AI and advanced applications, including quantum-safe encryption and various memory technologies [6] - The afternoon session will delve into automotive safety solutions, addressing trends and challenges faced by hardware and software designers in smart connected vehicles [7]

Core Viewpoint - The semiconductor industry faces critical challenges in data transmission speed and security, driven by the explosive growth of AI, connected vehicles, 5G, and IoT, leading to increased demand for high-performance computing and low-power chips [1] Group 1: Industry Challenges and Innovations - The bottlenecks in memory bandwidth and data processing security are becoming increasingly prominent [1] - Interface IP and security IP technologies are identified as core drivers for breakthroughs in the industry, directly impacting chip performance, compatibility, and attack resistance [1] Group 2: Company Overview - Rambus, established in 1990, is a pioneer in high-speed interface technology, redefining data transmission standards between memory and systems [1] - Rambus offers a robust product portfolio, including DDR memory interfaces, HBM3/4, and PCIe 5/6 solutions, significantly enhancing performance in data centers and edge computing [1] Group 3: Upcoming Event - Rambus will host a technology discussion on July 9, 2025, in Beijing, focusing on AI and automotive sectors, featuring industry partners and technical experts [2][3] - The event will cover the latest interface and security IP solutions for advanced applications, including quantum-safe encryption and various memory technologies [6] - The afternoon session will delve into automotive security solutions, addressing trends and challenges faced by hardware and software designers in smart connected vehicles [7]

June 2025 NasdaqGS: ZVRA 1 A Rare Approach to Therapeutics Cautionary Note Regarding Forward-Looking Statements Presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as "may," "will," "would," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," " ...

导读： InfinityBio完成800万美元A轮融资，收购Serimmune资产，推进MIPSA抗体分析平台开发，计划2025年推出新服务。 Infinit y Bio 周三表示，已经完成了 800 万美元的 A 轮融资。并以未披露的金额收购了免疫分析公司 Serimmune 的资产，Serimmune 成立于 2014 年，旨在提供无偏差的抗体反应组服务。包括 Env iroSIGHT 在内的新 MIPSA服务产品也预计将于 2025 年下半年推出。 本轮融资由 I l lumina Ventures 领投，PTX Capital、Blackbird BioVentures 和 Propel Baltimore Fund 参投。此前，该公司曾从包 括马里兰州的 PTX Capital 和 Blackbird BioVentures 在内的投资者那里筹集了 400 万美元的资金。Infinit y 表示，总部位于巴尔的摩 （美国马里兰州最大城市，美国大西洋沿岸重要海港城市），将利用这笔资金扩大其商业足迹，加速其 MIPSA 抗体分析平台的开发，并推出 新的免疫分析服务，收购 Serimmune 的资产是其扩 ...